90730-71-5

Usage

InChI:InChI=1/C19H26O6/c1-19(24,12-11-16-9-7-10-18(23)25-16)17(22)14-15(21)8-5-3-2-4-6-13-20/h2-8,10-12,15-17,20-22,24H,9,13-14H2,1H3/b3-2-,6-4+,8-5-,12-11+/t15-,16+,17+,19+/m0/s1

Upstream product

• 490020-99-0 Triethyl-[(R)-1-((E)-2-iodo-vinyl)-but-3-enyloxy]-silane 
• 490021-10-8 (3R)-(E)-1-iodohexa-1,5-dien-3-ol 
• 850146-93-9 Acrylic acid (E)-(1R,4R,5R,7R)-1-allyl-9-(benzyl-dimethyl-silanyl)-7-(tert-butyl-dimethyl-silanyloxy)-5-(3,4-dimethoxy-benzyloxymethoxy)-4-methyl-4-triethylsilanyloxy-non-2-en-8-ynyl ester 
• 850146-92-8 (E)-(3R,5R,6R,9R)-1-(Benzyl-dimethyl-silanyl)-3-(tert-butyl-dimethyl-silanyloxy)-5-(3,4-dimethoxy-benzyloxymethoxy)-6-methyl-9-triethylsilanyloxy-dodeca-7,11-dien-1-yn-6-ol 
• 850146-94-0 (R)-6-[(E)-(3R,4R,6R)-8-(Benzyl-dimethyl-silanyl)-6-(tert-butyl-dimethyl-silanyloxy)-4-(3,4-dimethoxy-benzyloxymethoxy)-3-methyl-3-triethylsilanyloxy-oct-1-en-7-ynyl]-5,6-dihydro-pyran-2-one 
• 850146-98-4 Acrylic acid (E)-(1R,4R,5R,7R)-1-allyl-9-(benzyl-dimethyl-silanyl)-7-(tert-butyl-dimethyl-silanyloxy)-5-(3,4-dimethoxy-benzyloxymethoxy)-4-hydroxy-4-methyl-non-2-en-8-ynyl ester 
• 850146-97-3 (E)-(4R,7R,8R,10R)-12-(Benzyl-dimethyl-silanyl)-10-(tert-butyl-dimethyl-silanyloxy)-8-(3,4-dimethoxy-benzyloxymethoxy)-7-methyl-dodeca-1,5-dien-11-yne-4,7-diol 
• 850146-95-1 (R)-6-((E,3R,4R,5R)-8-(benzyldimethylsilyl)-3-trimethylsiloxy-4-hydroxy-6-tert-butyldimethylsiloxybut-3-methyloct-1-en-7-ynyl)-5,6-dihydropyran-2-one 
• 850146-91-7 (3R,5R)-7-(Benzyl-dimethyl-silanyl)-5-(tert-butyl-dimethyl-silanyloxy)-3-(3,4-dimethoxy-benzyloxymethoxy)-hept-6-yn-2-one 
• 850146-90-6 (3R,5R)-7-(Benzyl-dimethyl-silanyl)-5-(tert-butyl-dimethyl-silanyloxy)-3-hydroxy-hept-6-yn-2-one 
• 850146-89-3 (3R,5R)-1-(Benzyl-dimethyl-silanyl)-6,6-diethoxy-hept-1-yne-3,5-diol 
• 850146-88-2 (R)-1-(Benzyl-dimethyl-silanyl)-6,6-diethoxy-5-hydroxy-hept-1-yn-3-one 
• 850146-96-2 (R)-6-[(1E,7Z)-(3R,4R,6R)-8-(Benzyl-dimethyl-silanyl)-6-(tert-butyl-dimethyl-silanyloxy)-4-hydroxy-3-methyl-3-triethylsilanyloxy-octa-1,7-dienyl]-5,6-dihydro-pyran-2-one 
• 87860-39-7 C₁₉H₂₆O₉P^(1-)*Na⁽¹⁺⁾ 

Downstream Products

• 187852-04-6 (6R,1'E,3'R,4'R,6'R,7'Z,9'Z,11'E)-6-(13'-tert-butyldiphenylsiloxy-3',4',6'-trihydroxy-3'-methyl-1',7',9',11'-tridecatetraenyl)-5,6-dihydro-2H-pyran-2-one 
• 187852-05-7 (3R,4Z,6Z,8E)-10-[(tert-bytyldiphenylsilyl)oxy]-4,6,8-decatriene-1,3-diol 
• 187851-93-0 (2E,4Z,6Z,8R)-8,10-bis(benzoyloxy)-1-[(tert-butyldiphenylsilyl)oxy]-2,4,6-decatriene 

Relevant academic research and scientific papers

Dinuclear asymmetric Zn aldol additions: Formal asymmetric synthesis of fostriecin

Direct asymmetric aldol reactions constitute a powerful methodology for the efficient synthesis of complex natural products. Herein we report the first application of our recently reported dinuclear Zn-catalyzed direct aldol addition of alkynyl ketones to

Novel Antitumor Agents CI-920, PD 113270 and PD 113271. 3. Structure Determination.

The chemical structures for the novel phosphate-containing antitumor agents CI-920 (1), PD 113270 (2), and PD 113271 (3) were determined by a combination of spectra and chemical means.Extensive analysis of NMR spectral data allowed tentative structures to be assigned for these compounds and their derivatives.These structures were confirmed by reducing CI-920 to 8-methyl-1-octadecanol and by cleaving dephosphorylated CI-920 (7) with sodium periodate to identified products.